Patent details

Basic Information

Publication number:

EP3534917

PCT Application Number:

US2017057863

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP178086278

PCT Publication Number:

WO2018080990

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL

French Title of Invention:

AMÉLIORATION DE PROPRIÉTÉS IMMUNOMODULATRICES DES CSM PAR LE TRÉPROSTINIL

German Title of Invention:

VERBESSERUNG DER MSC-IMMUNMODULATORISCHEN EIGENSCHAFTEN DURCH TREPROSTINIL

SPC Number:

Dates

Filing date:

23/10/2017

Grant date:

24/08/2022

EP Publication Date:

11/09/2019

PCT Publication Date:

03/05/2018

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

24/08/2022

EP B1 Publication Date:

24/08/2022

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

23/10/2022

Expiration date:

23/10/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

17/08/2022

 

 

Name:

United Therapeutics Corporation

Address:

1040 Spring Street, Silver Spring, MD 20910, United States (US)

Inventor

1

Name:

ILAGAN, Roger Marquez

Address:

United States (US)

2

Name:

CHEADLE, John B.

Address:

United States (US)

3

Name:

HOGAN, Sarah

Address:

United States (US)

Priority

Priority Number:

201662411950 P

Priority Date:

24/10/2016

Priority Country:

United States (US)

Classification

IPC classification:

A61K 35/28; C12N 5/0789; A61P 9/00; A61P 9/10; A61P 11/00;

Publication

European Patent Bulletin

Issue number:

202234

Publication date:

24/08/2022

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages